1. Home
  2. DCTH vs EOLS Comparison

DCTH vs EOLS Comparison

Compare DCTH & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$12.59

Market Cap

372.5M

Sector

Health Care

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$6.94

Market Cap

407.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCTH
EOLS
Founded
1988
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
372.5M
407.0M
IPO Year
2015
2018

Fundamental Metrics

Financial Performance
Metric
DCTH
EOLS
Price
$12.59
$6.94
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
5
Target Price
$22.00
$15.50
AVG Volume (30 Days)
579.8K
763.1K
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
107.53
1.23
EPS
N/A
N/A
Revenue
N/A
$297,176,000.00
Revenue This Year
$24.54
$13.27
Revenue Next Year
$33.15
$17.62
P/E Ratio
N/A
N/A
Revenue Growth
N/A
11.61
52 Week Low
$8.12
$3.86
52 Week High
$13.44
$10.20

Technical Indicators

Market Signals
Indicator
DCTH
EOLS
Relative Strength Index (RSI) 63.23 60.63
Support Level $10.26 $6.44
Resistance Level N/A $7.36
Average True Range (ATR) 0.57 0.30
MACD 0.12 0.01
Stochastic Oscillator 76.05 64.44

Price Performance

Historical Comparison
DCTH
EOLS

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

Share on Social Networks: